Disease Events Radiation Radiopharmaceuticals 
AuntMinnie
SEPTEMBER 30, 2024
A radiopharmaceutical therapy that lengthens progression-free survival for patients with neuroendocrine cancer could help treat meningioma sufferers, according to research presented at the American Society for Radiation Oncology (ASTRO) meeting. The researchers also tracked overall survival and rates of adverse events.
Imaging Technology
AUGUST 29, 2023
The event marks a key milestone in the exclusive Cu-67 supply agreement between both companies. Once securely attached to a targeting molecule, the chelated Cu-67 delivers therapeutic doses of radiation to destroy cancer cells with limited damage to healthy tissue.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
AuntMinnie
MARCH 26, 2024
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.
AuntMinnie
OCTOBER 2, 2024
Ultrasound model predicts liver disease progression. Commercially Available Chest Radiograph AI Tools for Detecting Airspace Disease, Pneumothorax, and Pleural Effusion. Effects of low-dose ionizing radiation on genomic instability in interventional radiology workers. SPECT/CT reveals heart’s response to tafamidis.
Imaging Technology
SEPTEMBER 27, 2023
PET imaging with POSLUMA reveals clinical information crucial to decision-making for men with prostate cancer, and we are excited to share further information with the radiation oncology community at ASTRO 2023,” said David E. Jani, MD, FASTRO, Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Ga.,
AuntMinnie
JUNE 20, 2024
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.
Imaging Technology
OCTOBER 5, 2023
Effective initial staging of prostate cancer, particularly with regards to the detection of metastatic disease, is critical to optimal clinical management of patients,” said Phillip H. Such information can help guide treatment selection and potentially avoid futile surgery for patients with high-risk disease.” “We
Expert insights. Personalized for you.
119 
Let's personalize your content